Results 301 to 310 of about 260,030 (390)

Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background Emerging RAS inhibitors show promise in treating KRAS‐mutated malignancies, but resistance mechanisms limit their clinical efficacy. Given recent clinical findings associating KRAS mutations with reduced response to neoadjuvant therapy in rectal cancer (RC), we aimed to investigate their impact on treatment outcomes and explore ...
Jonas Buchloh, Melanie Spitzner, Hauke Zimmermann, Xin Fang, Constanza Tapia Contreras, Carolin Schneider, Tiago de Oliveria, Stefan Küffer, Michael Linnebacher, Felix Rühlmann, Lena Conradi, Matthias Wirth, Michael Ghadimi, Marian Grade, Jochen Gaedcke, Günter Schneider   +15 more
wiley   +1 more source

Discovery of KRAS(G12D) selective degrader ASP3082. [PDF]

Commun Chem
Yoshinari T, Nagashima T, Ishioka H, Inamura K, Nishizono Y, Tasaki M, Iguchi K, Suzuki A, Sato C, Nakayama A, Amano Y, Tateishi Y, Yamanaka Y, Osaki F, Yoshino M, Kuramoto K, Imaizumi T, Hayakawa M.   +17 more
europepmc   +1 more source

KRAS Mutation Limits Response to Anti-EGFR Antibodies in First-Line & Previously Treated Colorectal Cancer Patients

, 2008
Rabiya S. Tuma
openalex   +1 more source

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Cell, 2018
M. R. Janes, Jingchuan Zhang, Lian-Sheng Li, R. Hansen, U. Peters, Xin Guo, YuChing Chen, Anjali Babbar, Sarah J. Firdaus, L. Darjania, Jun Feng, Jeffrey H. Chen, Shuangwei Li, Shisheng Li, Y. Long, C. Thach, Yuan Liu, Ata Zarieh, T. Ely, Jeff M. Kucharski, L. Kessler, Tao Wu, K. Yu, Yi Wang, Y. Yao, Xiaohu Deng, P. Zarrinkar, D. Brehmer, D. Dhanak, M. V. Lorenzi, D. Hu-Lowe, M. Patricelli, Pingda Ren, Yi Liu   +33 more
semanticscholar   +1 more source

Real‐World Molecular Testing in European Early‐Onset Colorectal Cancer

United European Gastroenterology Journal, EarlyView.
ABSTRACT Purpose The global incidence and mortality of early‐age onset colorectal cancer (EOCRC, or CRC diagnosed under 50 years) has increased in recent decades. High‐risk surveillance and personalised oncological treatment may improve patients' outcomes.
Penelope V. Edwards, Kussai Giuma Ali Eloussta, Andrew Latchford, Omar Faiz, Huw Thomas, Filomena Liccardo, Nikhil Pawa, Robert Hüneburg, Jacob Nattermann, Andrew George, Francesc Balaguer, Marc Martí, Antonino Spinelli, Caterina Foppa, Noel F. F. C. de Miranda, Irene López, Elena Hurtado, Fernando Jiménez, Marta Jiménez‐Toscano, Edurne Álvaro, Gonzalo Sanz, Araceli Ballestero, José A. Rueda, Cristina Viyuela, Lorena Brandáriz, Rosario Vidal‐Tocino, Damián García‐Olmo, Carlos Pastor, Rogelio González‐Sarmiento, Andreana N. Holowatyj, Terri McVeigh, José Perea, Kevin J. Monahan, On behalf of Collaborators GEOCODE and SECOC Consortia   +33 more
wiley   +1 more source

Emerging Targets in Non-Small Cell Lung Cancer. [PDF]

Lung Cancer (Auckl)
Wang J, Biglow L, Baumgart M.
europepmc   +1 more source

Faculty Opinions recommendation of Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.

, 2008
Isaac S. Kohane
openalex   +1 more source

Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions

United European Gastroenterology Journal, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, mainly due to its aggressive nature, early metastasis, diagnosis at late stages, and limited response to systemic anticancer therapy. Perineural invasion (PNI), defined as the infiltration of neoplastic cells along nerve fibers and within nerve sheaths, is ...
Martin Lovecek, Esra Dirimtekin, Ingrid Garajová, Giulia Gasparini, Stefano Crippa, Elisa Giovannetti, Dana Sochorova, Carmen Mota Reyes, Ihsan Ekin Demir, Pinar Uysal‐Onganer, on behalf TRANSPAN PNI Group   +10 more
wiley   +1 more source

Post-transcriptional control of KRAS: functional roles of 5'UTR RNA G-quadruplexes, long noncoding RNA, and hnRNPA1. [PDF]

Nucleic Acids Res
Cortolezzis Y, Othman Z, Agostini F, Ibrahim I, Picco R, Salgado GF, Di Giorgio E, Xodo LE.   +7 more
europepmc   +1 more source

Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures

United European Gastroenterology Journal, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with chemotherapy as the mainstay but highly variable efficacy and toxicity. Current regimens, such as FOLFIRINOX and gemcitabine‐based combinations, are selected empirically without validated biomarkers to guide choice.
Brice Chanez, Matthieu Delaye, Nicolas Fraunhoffer, Juan Iovanna, Cindy Neuzillet, Nelson Dusetti   +5 more
wiley   +1 more source